{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:46:51Z","timestamp":1782330411397,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00520-025-10281-7","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:21:57Z","timestamp":1766571717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and risk factors of MRONJ in breast cancer patients with CTIBL"],"prefix":"10.1007","volume":"34","author":[{"given":"Christian","family":"Bacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Roccuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Boccuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Falci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Zovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Watutantrige - Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"#cr-split#-10281_CR1.1","unstructured":"International Agency for Research on Cancer. Cancer Today. Data version: GLOBOCAN 2022 (version 1.1). Lyon, France: IARC"},{"key":"#cr-split#-10281_CR1.2","unstructured":"2024 [access 2025 Aug 13]. Available from: https:\/\/gco.iarc.who.int"},{"issue":"3","key":"10281_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/sj.bjc.6604532","volume":"99","author":"D Puliti","year":"2008","unstructured":"Puliti D, Miccinesi G, Collina N, Manneschi G, Paci E (2008) Effectiveness of service screening: a case\u2013control study to assess breast cancer mortality reduction. Br J Cancer 99(3):423\u2013427","journal-title":"Br J Cancer"},{"key":"10281_CR3","unstructured":"Gori S (2023) Linee guida AIOM: Carcinoma mammario in stadio precoce. Edizione 2023. Milan: Intermedia Editore"},{"key":"10281_CR4","unstructured":"Associazione Italiana di Oncologia Medica (AIOM) (2023) Linee guida: carcinoma mammario in stadio precoce. Rome: Sistema Nazionale Linee Guida (SNLG), Istituto Superiore di Sanit\u00e0 p. 1\u2013742"},{"key":"10281_CR5","doi-asserted-by":"crossref","unstructured":"Bui KT, Willson ML, Goel S, Beith J, Goodwin A (2020) Cochrane Breast Cancer Group. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst Rev. (3):CD013538","DOI":"10.1002\/14651858.CD013538"},{"key":"10281_CR6","doi-asserted-by":"crossref","unstructured":"Pagani O, Walley BA, Fleming GF, Colleoni M, L\u00e1ng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan MM, Francis PA (2023) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol 41(7):1376\u20131382","DOI":"10.1200\/JCO.22.01064"},{"issue":"34","key":"10281_CR7","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cort\u00e9s J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O\u2019Shaughnessy J, Rastogi P (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer. J Clin Oncol 38(34):3987\u20133998","journal-title":"J Clin Oncol"},{"key":"10281_CR8","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast cancer, Version 3.2024. National Comprehensive Cancer Network. 2024. [access 2025 Aug 13] Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419"},{"key":"10281_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-11-384","volume":"11","author":"JJ Body","year":"2011","unstructured":"Body JJ (2011) Increased fracture rate in women with breast cancer: a review of the hidden risk. BMC Cancer 11:1\u20139","journal-title":"BMC Cancer"},{"issue":"6","key":"10281_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","volume":"38","author":"P Hadji","year":"2012","unstructured":"Hadji P, Gnant M, Body JJ, Brandi ML, Ebeling PR, Elsabakhy A et al (2012) Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev 38(6):798\u2013806","journal-title":"Cancer Treat Rev"},{"key":"10281_CR11","doi-asserted-by":"crossref","unstructured":"Bedogni A, Mauceri R, Fusco V, Bertoldo F, Bettini G, Di Fede O, Lo Casto A, Marchetti C, Panzarella V, Saia G, Vescovi P, Campisi G. Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). Oral Dis. 2024 Sep;30(6):3679-3709","DOI":"10.1111\/odi.14887"},{"key":"10281_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115501","volume":"139","author":"S Cremers","year":"2020","unstructured":"Cremers S, Ebetino FH, Phipps R (2020) On the pharmacological evaluation of bisphosphonates in humans. Bone 139:115501","journal-title":"Bone"},{"issue":"2","key":"10281_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","volume":"29","author":"AE Kearns","year":"2008","unstructured":"Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29(2):155\u2013192","journal-title":"Endocr Rev"},{"key":"10281_CR14","volume-title":"Raccomandazioni clinico-terapeutiche sull'osteonecrosi delle ossa mascellari (ONJ) farmaco-relata e sua prevenzione","author":"G Campisi","year":"2020","unstructured":"Campisi G, Bedogni A, Fusco V (2020) Raccomandazioni clinico-terapeutiche sull\u2019osteonecrosi delle ossa mascellari (ONJ) farmaco-relata e sua prevenzione. New Digital Press, Palermo, Italy"},{"issue":"5","key":"10281_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update. J Oral Maxillofac Surg 80(5):920\u2013943","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"10281_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12903-023-02732-6","volume":"23","author":"R Mauceri","year":"2023","unstructured":"Mauceri R, Coppini M, Attanasio M, Panzarella V, Catalfamo L, Scapellato S et al (2023) Mronj in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series. BMC Oral Health 23(1):71","journal-title":"BMC Oral Health"},{"issue":"2","key":"10281_CR17","first-page":"98","volume":"92","author":"G Campisi","year":"2024","unstructured":"Campisi G, Bedogni A, Fusco V, Mauceri R, Panzarella V, Scapellato S et al (2024) Joint report SIPMO-SIOMMMS sulla MRONJ in pazienti in cura con antiriassorbitivi per prevenire la CTIBL \/ A joint report of SIPMO and SIOMMMS on MRONJ in patients under BMA therapy for CTIBL prevention. Oral Dis 92(2):98\u2013117","journal-title":"Oral Dis"},{"key":"10281_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100656","volume":"50","author":"F Bertoldo","year":"2024","unstructured":"Bertoldo F, Eller-Vainicher C, Fusco V, Mauceri R, Pepe J, Bedogni A, Palermo A, Romeo U, Guglielmi G, Campisi G (2024) Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS. J Bone Oncol 50:100656","journal-title":"J Bone Oncol"},{"key":"10281_CR19","doi-asserted-by":"crossref","unstructured":"Bacci C, Cerrato A, Bardhi E, Frigo AC, Djaballah SA, Sivolella S. A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities. Support Care Cancer. 2022 Feb;30(2):1723-1729","DOI":"10.1007\/s00520-021-06587-x"},{"issue":"1","key":"10281_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdn554","volume":"20","author":"M Dimopoulos","year":"2009","unstructured":"Dimopoulos M, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20(1):117\u2013120","journal-title":"Ann Oncol"},{"issue":"11","key":"10281_CR21","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"RE Marx","year":"2005","unstructured":"Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63(11):1567\u20131575","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"10281_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown J, Van Poznak C, Ibrahim T, Stemmer S, Diel IJ et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23(5):1341\u20131347","journal-title":"Ann Oncol"},{"issue":"4","key":"10281_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","volume":"66","author":"JH Wessel","year":"2008","unstructured":"Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66(4):625\u2013631","journal-title":"J Oral Maxillofac Surg"},{"key":"10281_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9858921","volume":"2018","author":"R Sacco","year":"2018","unstructured":"Sacco R, Sacco N, Hamid U, Ali SH, Singh M, Blythe JSJ (2018) Microsurgical reconstruction of the jaws using vascularised free flap technique in patients with medication-related osteonecrosis: a systematic review. Biomed Res Int 2018:9858921","journal-title":"Biomed Res Int"},{"issue":"8","key":"10281_CR25","volume":"32","author":"N Yarom","year":"2024","unstructured":"Yarom N, Van Poznak CH, Epstein JB, Ottaviani G, Matsuda Y, Migliorati C, Elad S (2024) MASCC\/ISOO clinical practice statement: adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw. Support Care Cancer 32(8):547","journal-title":"Support Care Cancer"},{"issue":"4","key":"10281_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1759720X18759291","volume":"10","author":"OL Tseng","year":"2018","unstructured":"Tseng OL, Spinelli JJ, Gotay CC, Ho WY, McBride ML, Dawes MG (2018) Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis 10(4):71\u201390","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"10281_CR27","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","volume":"123","author":"S Fedele","year":"2010","unstructured":"Fedele S, Porter SR, D\u2019Aiuto F, Thomson P, Bagan JV, Kubler A et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123(11):1060\u20131064","journal-title":"Am J Med"},{"issue":"12","key":"10281_CR28","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1016\/j.joms.2009.07.097","volume":"67","author":"G Colella","year":"2009","unstructured":"Colella G, Campisi G, Fusco V (2009) American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws\u20142009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 67(12):2698\u20132699","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10281-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:03:05Z","timestamp":1782327785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10281-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10281"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10281-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}